Is Vanquoryn Delftavix a Scam?

Vanquoryn Delftavix presents itself as a cutting-edge AI-powered trading platform targeting Dutch investors, promising effortless access to stocks and cryptocurrencies with a low entry barrier of just €250. Its website, vanquoryn-delftavix.nl, boasts over 3,200 users and a 4.8-star rating, while third‑party promotional articles paint a picture of automated wealth‑building. But behind the polished marketing lies a far more concerning reality: a complete absence of verifiable regulatory oversight and a corporate structure shrouded in opacity.

At FXCanary, we have scrutinised hundreds of brokers, and our safety methodology is built on three pillars: regulatory credentials, transparency of ownership, and real‑world user feedback. For Vanquoryn Delftavix, the gaps are glaring. No independent user reviews exist yet, and the entity is not registered with any financial authority — not the Dutch AFM, not the DNB, not any respected international regulator. In this deep‑dive safety article, we dissect what this means for your funds and why our Scam Risk Score sits at an elevated 55 out of 100.

Our assessment of a broker’s safety always starts with the regulatory licence. A valid licence from a reputable authority — such as the FCA in the UK, CySEC in Cyprus, or the AFM in the Netherlands — imposes strict rules on capital adequacy, client‑fund segregation, and regular audits. It also typically grants access to a compensation scheme if the firm fails. We then cross‑reference the licence number against the official public register; a genuine licence can be verified in seconds.

The second pillar is corporate transparency. Who owns the broker? Where is it incorporated?

What is the management track record? Legitimate brokers proudly display these details, often with a physical address and a clear complaints procedure. Finally, we weigh the collective experience of actual users — independent reviews, forum threads, and complaint records.

Where user feedback is non‑existent, as with Vanquoryn Delftavix, the regulatory and transparency metrics become even more critical.

Because Vanquoryn Delftavix has no regulatory licence on file and provides no verifiable company information, our Scam Risk Score of 55/100 reflects a heightened probability of adverse outcomes. It is not a score we assign lightly, but it is a necessary warning when a broker appears to operate in a legal vacuum.

Our investigation confirms that Vanquoryn Delftavix holds no regulatory licence, anywhere in the world. The Dutch Authority for the Financial Markets (AFM) and De Nederlandsche Bank (DNB) maintain public registers of all authorised financial service providers in the Netherlands; a search for ‘Vanquoryn Delftavix’ returns no results. Similarly, cross‑checks with the FCA, BaFin, and other major registries come up empty. The broker’s website does not claim any regulatory status — it simply omits the topic altogether.

This is a fundamental red flag. In the Netherlands, offering investment services without an AFM or DNB licence is illegal, and yet the platform markets itself aggressively to Dutch residents, even using a .nl domain and Dutch‑language content. The absence of regulation means there is no legal requirement to segregate client money from company funds, no minimum capital buffer, and no external oversight of trading practices.

In practice, you are handing your deposit to an anonymous entity that could vanish overnight with no route to recovery. The €250 starting deposit, presented as an affordable entry point, is entirely unprotected by any compensation scheme. The regulatory void is not a mere technicality; it is the single most important reason to approach this broker with extreme caution.

When you open an account with a regulated broker, your funds must be held in segregated client accounts at top‑tier banks, separated from the firm’s operational cash. If the broker goes insolvent, your money is ring‑fenced and should be returned to you, subject to administrator verification. On top of that, most European‑regulated brokers are required to participate in an investor compensation scheme (ICS), which covers up to €20,000 per person in the Netherlands and similar amounts elsewhere, should the broker fail despite segregation.

Negative balance protection is another crucial shield: authorised CFD brokers in the EU are obligated to limit retail client losses to the deposited amount. Without regulation, Vanquoryn Delftavix is not bound by any of these rules. The platform’s terms and conditions, which we examined on its website, make no mention of segregated accounts, compensation coverage, or negative balance protection. They merely state that it “connects” investors with financial advisers — a vague description that could mask a wide range of risky activities.

In other words, your deposit is entirely at the mercy of the operator’s integrity and liquidity. There is no safety net. If the platform were to collapse due to market volatility, fraud, or simple mismanagement, you would likely become an unsecured creditor with little hope of recovering your funds.

Transparency is the first line of defence against fraud. Regulated brokers list their corporate registration number, legal entity name, and physical headquarters prominently. Vanquoryn Delftavix provides none of this. The website offers only a generic contact email (support@vanquoryn-delftavix.nl) and a copyright notice with no legal entity specified. A WHOIS lookup on the domain reveals privacy‑protected registration details, a common tactic used by operators who wish to remain untraceable.

The ‘About’ page speaks in sweeping terms about vision and values but offers no names of founders, executives, or team members. There is no LinkedIn presence, no press releases, no verifiable track record. When we encounter this level of anonymity alongside a platform soliciting deposits, our internal risk algorithms flag it as a strong indicator of a potentially fraudulent or, at best, highly speculative venture.

Even the promotional review sites that shower Vanquoryn Delftavix with praise fail to identify the company behind the brand. Such “review” sites are often paid promotions, designed to funnel readers toward the platform via affiliate links. Without a legal face, Vanquoryn Delftavix remains a ghost — and trusting a ghost with your money is never advisable.

Clone scams are a persistent menace in the online trading world: fraudsters create websites that mimic legitimate financial firms, often down to the logo and colour scheme. While we have found no evidence that Vanquoryn Delftavix is directly cloning an existing regulated broker, the risk of brand impersonation still swirls. We discovered at least one alternative domain — vanquoryndelftavix-nl.com — that mirrors the official site, suggesting either a network of affiliated clone sites or a preparedness to quickly redeploy if the main domain is flagged.

The platform’s website makes use of stock imagery and generic claims about AI engines and real‑time analysis, patterns often seen in boiler‑room operations that pivot from one brand to another. The marketing language (“maximale winstkansen,” “slimme geldbeleggingen zonder barrières”) is emotionally charged and avoids any substantive risk disclosures.

If a firm is willing to flout basic licensing requirements, it could just as easily change names overnight. A clone risk isn’t always about impersonating a known brand; it’s about the possibility that the same operators have multiple fronts. Traders who deposit with one unlicensed entity may find their personal data being used to target them under a different name later.

Our primary advice is straightforward: do not deposit money with an unregulated broker. The lure of low entry barriers and AI‑powered profits is powerful, but the absence of a licence is a deal‑breaker. Before opening any account, take five minutes to verify the broker’s regulation on the official register of the authority claimed. A genuine broker will provide a licence number you can cross‑reference. If none is displayed, assume the worst.

Even when a broker claims a licence, check the domain name carefully; clone sites often use slight misspellings. For Vanquoryn Delftavix specifically, we found no licence to verify. The only sensible course is to walk away. If you have already deposited, test the withdrawal process immediately with a small amount; refusal, delays, or pressure to deposit more before a withdrawal are classic scam signs.

Use the official financial consumer warnings published by the AFM, DNB, or ESMA. These agencies regularly issue alerts about unauthorised firms. Finally, rely on trusted, well‑established brokers that are transparent about their parent company and regulatory status. In the Netherlands, many reputable international brokers operate under a passporting regime, giving you full EU protections.

Vanquoryn Delftavix checks none of the boxes we require for a safe trading environment. It is unregulated, opaque, and targets Dutch investors in a jurisdiction where investment services without a licence are illegal. The elevated Scam Risk Score of 55 is not an indictment on its own, but a reflection of the profound risk you take when entrusting funds to a completely unknown entity.

In our assessment, the marketing narrative of easy AI profits is a red herring designed to distract from the missing fundamentals. There is no segregation of funds, no compensation scheme, and no legal pathway to recourse if things go wrong. The lack of independent user reviews, while not proof of fraud, means you have zero experiential evidence to balance the glossy promises.

Until Vanquoryn Delftavix obtains a verifiable licence from a reputable regulator and discloses its legal structure and management, we strongly advise against opening an account. In the world of online trading, regulatory compliance is not a luxury — it is the minimum price of entry for your trust.